Resources
33 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Engagement in drug treatment following nonfatal overdose among people who inject drugs in Appalachia
Posted 6/2/2021 (updated 4/10/2024)
Immediately after experiencing a non-fatal overdose, many people who inject drugs (PWID) engage in harm-minimizing behavior change, including engagement in drug treatment. To inform the implementation of tailored interventions designed to facilitate drug treatment engagement in rural communities, we sought to identify correlates of starting any form of drug treatment after their most recent overdose among PWID who reside in a rural county in West Virginia.
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 3/25/2021 (updated 4/5/2024)
Recovery Housing, Medications for OUD (MOUD), and Emerging Issues
Presenters will explain recovery housing and MOUD in the context of issues emerging in rural America resulting from the pandemic and its impact on the rates of substance use disorder (SUD) and drug overdose. They will discuss the impact of the pandemic on the correctional system and state actions in response to COVID-19 as it affects those with SUD. They will also give an overview of how recovery housing can be developed, especially in rural areas.
Posted 3/6/2021 (updated 4/5/2024)
HepVu released new interactive maps visualizing U.S. county-level Hepatitis C-related mortality, illustrating how factors such as age and geographic region affect health outcomes. Published in Hepatology, the data demonstrate that Hepatitis C-related mortality has been decreasing across the U.S. since 2013
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 12/15/2020 (updated 4/3/2024)
This presentation discussed the evolution of North Carolina’s formerly siloed sectors: prevention, treatment, & recovery. The introduction of Recovery Community Center (RCC) funding helped to develop a network of community-based recovery support services. However, when one of NC’s strongest prevention coalitions received RCC funding, they took it to another level. Keeping strongly rooted in its prevention identity, they expanded their growth into authentic recovery support services and non-arrest diversion partnerships with local law enforcement and treatment providers. Implementation II grantee Wilson Substance Prevention Coalition illustrated some of its full continuum of care programming and how it has adapted to the pandemic’s challenges
Posted 12/15/2020 (updated 4/3/2024)
The presenter reviewed considerations in engaging and treating individuals with stimulant use disorders and presented evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 10/14/2021 (updated 4/3/2024)
Presenters explained the role of RH in the continuum of care in this exciting and interactive presentation on emerging topics related to integrating social and medical models of recovery. They focused on emerging issues in rural America resulting from the pandemic, its impact on the rates of substance use disorder (SUD), and use of RH. Presenters emphasized funding for the development of RH, the role of partnerships within the recovery ecosystem, and promising practices involving cross-sector collaboration in housing, corrections, treatment, and recovery supports.
Milena Stott, LICSW, SUDP, The Fletcher Group
Erica Walker, CSW, TCADC, The Fletcher Group
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence